Small cardioactive peptide B
Need Assistance?
  • US & Canada:
    +
  • UK: +

Small cardioactive peptide B

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Small Cardioactive Peptide B (SCPB), a neurally active peptide, stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with EC50s of 0.1 and 1.0 μM, respectively.

Category
Peptide Inhibitors
Catalog number
BAT-010660
CAS number
84746-43-0
Molecular Formula
C52H80N14O11S2
Molecular Weight
1141.41
Small cardioactive peptide B
IUPAC Name
(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]butanediamide
Synonyms
SCPB; Met-asn-tyr-leu-ala-phe-pro-arg-met-NH2
Purity
98%
Density
1.41 g/cm3
Sequence
MNYLAFPRM
InChI
InChI=1S/C52H80N14O11S2/c1-29(2)25-37(63-48(74)38(26-32-15-17-33(67)18-16-32)64-49(75)39(28-42(54)68)62-45(71)34(53)19-23-78-4)47(73)59-30(3)44(70)65-40(27-31-11-7-6-8-12-31)51(77)66-22-10-14-41(66)50(76)61-36(13-9-21-58-52(56)57)46(72)60-35(43(55)69)20-24-79-5/h6-8,11-12,15-18,29-30,34-41,67H,9-10,13-14,19-28,53H2,1-5H3,(H2,54,68)(H2,55,69)(H,59,73)(H,60,72)(H,61,76)(H,62,71)(H,63,74)(H,64,75)(H,65,70)(H4,56,57,58)/t30-,34-,35-,36-,37-,38-,39-,40-,41-/m0/s1
InChI Key
IDATZUYVZKJKRE-SXMXEBDWSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NC(CCSC)C(=O)N)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)N
1. FMRFamide-like immunocytochemistry in the brain and subesophageal ganglion of Triatoma infestans (Insecta: Heteroptera). Coexpression with beta-pigment-dispersing hormone and small cardioactive peptide B
Beatriz P Settembrini, Marcelo J Villar Cell Tissue Res. 2005 Aug;321(2):299-310. doi: 10.1007/s00441-005-1147-z. Epub 2005 Jun 10.
The distribution of FMRFamide (FMRFa)-like immunoreactivity (LI) was studied in the brain and subesophageal ganglion of Triatoma infestans, the insect vector of Chagas' disease. The neuropeptide displayed a widespread distribution with immunostained somata in the optic lobe, in the anterior, lateral, and posterior soma rinds of the protocerebrum, and around the antennal sensory and mechanosensory and motor neuropils of the deutocerebrum. FMRFa-immunoreactive profiles of the subesophageal ganglion were seen in the mandibular, maxillary, and labial neuromeres. Immunostained neurites were detected in the medulla and lobula of the optic lobe, the lateral protocerebral neuropil, the median bundle, the calyces and the stalk of the mushroom bodies, and the central body. In the deutocerebrum, the sensory glomeruli showed a higher density of immunoreactive processes than the mechanosensory and motor neuropil, whereas the neuropils of each neuromere of the subesophageal ganglion displayed a moderate density of immunoreactive neurites. Colocalization of FMRFa-LI and crustacean pigment-dispersing hormone-LI was found in perikarya of the proximal optic lobe, the lobula, the sensory deutocerebrum, and the labial neuromere of the subesophageal ganglion. The distribution pattern of small cardioactive peptide B (SCP(B))-LI was also widespread, with immunolabeled somata surrounding every neuropil region of the brain and subesophageal ganglion, except for the optic lobe. FMRFa- and SCP(B)-LIs showed extensive colocalization in the brain of this triatomine species. The presence of immunolabeled perikarya displaying either FMRFa- or SCP(B)-LI confirmed that each antisera identified different peptide molecules. The distribution of FMRFa immunostaining in T. infestans raises the possibility that FMRFa plays a role in the regulation of circadian rhythmicity. The finding of immunolabeling in neurosecretory somata of the protocerebrum suggests that this neuropeptide may also act as a neurohormone.
2. The effects of small cardioactive peptide B on the isolated heart and gill of Aplysia californica
D R Cawthorpe, J Rosenberg, W F Colmers, K Lukowiak, G I Drummond Can J Physiol Pharmacol. 1985 Aug;63(8):918-24. doi: 10.1139/y85-152.
Effects of small cardioactive peptide B on the physiology of the isolated heart and gill preparations from the mollusc Aplysia californica were examined. In addition, the effects of small cardioactive peptide B and FMRFamide (Phe-Met-Arg-Phe-NH2) on adenylate cyclase activity were compared in particulate fractions of heart and gill tissues, respectively. Small cardioactive peptide B was found to exert dose-dependent, reversible changes in cardiac activity when perfused through the isolated heart. The EC50 values effecting changes in heart rate and force of contraction were 3 X 10(-11) and 3 X 10(-10) M, respectively; minimum concentrations found to effect changes in heart rate and force of contraction were normally 10(-15) and 10(-12) M, respectively. However, some winter hearts demonstrated threshold sensitivity to small cardioactive peptide B at concentrations as low as 10(-17) M. When perfused through the isolated gill, small cardioactive peptide B was found to suppress the gill withdrawal response amplitude with a threshold concentration of 10(-14) M and an EC50 value of 3 X 10(-11) M. Suppression of the gill withdrawal response amplitude by small cardioactive peptide B was found to be dose dependent and reversible up to a concentration of 10(-9) M. At higher concentrations, the suppression tended to persist irreversibly. Small cardioactive peptide B stimulated adenylate cyclase activity in particulate fractions of both heart and gill tissues with an EC50 of 0.1 and 1.0 microM, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
3. The small cardioactive peptides A and B of Aplysia are derived from a common precursor molecule
A C Mahon, P E Lloyd, K R Weiss, I Kupfermann, R H Scheller Proc Natl Acad Sci U S A. 1985 Jun;82(11):3925-9. doi: 10.1073/pnas.82.11.3925.
We have identified cells in the central nervous system of the marine mollusc Aplysia that react with antibody raised against the small cardioactive peptide B (SCPB). Antisera to this neuropeptide stained a subset of central neurons that include the large identified buccal neurons, B1 and B2. The distribution of SCP-containing neurons was used in a strategy to isolate a cDNA clone encoding the precursor protein for the peptide. RNA from neurons B1 and B2 and from cells that did not stain with SCPB antisera was used to direct the synthesis of radiolabeled cDNA probes. A cDNA clone complimentary to mRNA specifically expressed in the B1 and B2 cells was isolated by differentially screening a buccal cDNA library with these probes. The cloned cDNA segment is 1394 nucleotides in length and contains a 408-base-pair open reading frame. The predicted precursor protein is composed of 136 amino acids and has a characteristic hydrophobic leader sequence. The sizes of the precursor protein with and without this leader sequence agree with in vivo and in vitro labeling studies. The amino acid sequences for SCPB and a related peptide, SCPA, are present and are flanked by known proteolytic processing sites.
Online Inquiry
Verification code
Inquiry Basket